TWST
Twist Bioscience Corp
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$139.77
+5.29%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$136.99
From 52W high−31.82%
Volume1.59M
Market cap$9.27B
P/E (TTM)—
P/S (TTM)21.5x
Div yield—
Key dataOct 19, 2026
Open
$136.99
From 52W high
−31.82%
Volume
1.59M
Market cap
$9.27B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−85.3x
P/E (TTM)
—
RSI (14)
42.3
MomentumView details →
1D Return
+5.29%
YTD Return
+340.67%
SummaryUpdated Jun 1, 2026
Twist Bioscience Corporation (NASDAQ:TWST) is a synthetic biology company founded in 2013 and headquartered in South San Francisco, California. The company went public in October 2018 and has established itself as a leader in DNA synthesis technology. Twist operates a proprietary silicon-based DNA synthesis platform that enables the manufacturing of synthetic DNA by literally "writing" DNA sequences on silicon chips, similar to how computer chips are manufactured. The company has grown from a startup to serving over 3,500 customers globally across academic, biotechnology, pharmaceutical, and industrial markets.
Similar companies
Latest newsMore news →
Twist Bioscience Corp. shares pulled back on Friday after touching a fresh 52-week high near $192 earlier in the session.24d agoTwist Bioscience stock rose more than 31% over the week following its Lilly TuneLab announcement.31d agoTwist Bioscience Corporation announced an agreement with Lilly TuneLab, Eli Lilly's collaborative AI/ML drug discovery platform.33d ago